Assembly Biosciences, Inc. (NASDAQ:ASMB) – Stock analysts at William Blair increased their FY2017 earnings estimates for Assembly Biosciences in a research note issued on Monday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will earn ($2.95) per share for the year, up from their previous estimate of ($3.40). William Blair also issued estimates for Assembly Biosciences’ Q4 2017 earnings at ($0.66) EPS, FY2018 earnings at ($3.18) EPS and FY2019 earnings at ($3.55) EPS.
ILLEGAL ACTIVITY WARNING: This piece was posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.themarketsdaily.com/2017/11/16/william-blair-analysts-raise-earnings-estimates-for-assembly-biosciences-inc-asmb.html.
Shares of Assembly Biosciences (NASDAQ ASMB) opened at $33.13 on Wednesday. Assembly Biosciences has a 12-month low of $11.07 and a 12-month high of $36.31.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Nationwide Fund Advisors bought a new position in Assembly Biosciences in the second quarter worth $161,000. Parametric Portfolio Associates LLC raised its holdings in Assembly Biosciences by 13.6% in the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 1,203 shares in the last quarter. Legal & General Group Plc bought a new position in Assembly Biosciences in the second quarter worth $212,000. Wells Fargo & Company MN bought a new position in Assembly Biosciences in the second quarter worth $213,000. Finally, Trexquant Investment LP bought a new position in Assembly Biosciences in the second quarter worth $217,000. Institutional investors and hedge funds own 62.19% of the company’s stock.
In related news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 19.60% of the stock is owned by corporate insiders.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.